Dr. Luis Izquierdo López has been appointed as Chief Medical Officer (CMO) for Veritas Intercontinental, Europe & Latam, subsidiary of Veritas Genetics, The Genome Company.
Bachelor of Medicine and Surgery from the Complutense University of Madrid, doctor of Obstetrics and Gynecology, with extraordinary prize from the Faculty of Medicine of the UCM and Master Science in Medical Genetics by Glasgow University, Dr. Luis Izquierdo will be the Chief Medical Officer of all the territories where Veritas Int. operates or what is the same, in Europe, Latin America, Japan and United Arab Emirates.
Medical specialist in clinical genetics, trained in the main units of Genetics inside and outside Spain, Dr. Luis Izquierdo adds to his curriculum more than 25 years of practice in clinical and laboratory genetics, and a very important scientific activity in fields such as screening of pregnant women with risk of Down syndrome and other chromosomal abnormalities, prenatal diagnosis, familial cancer or hereditary heart diseases.
Prior to joining Veritas, Dr. Izquierdo developed his professional activity as director of the Genetics area of SYNLAB Laboratories, without abandoning clinical practice as Head of the Genetics Service of Hospital de la Zarzuela, Hospital de Torrejón and Consultant in Genetics of the Alcorcón Foundation University Hospital.
About Veritas Intercontinental
Veritas Intercontinental is the international subsidiary of Veritas Genetics, The Genome Company, which operates in Europe, Latin America, Japan and UAE. Its mission is to promote whole genome and offer people information that empowers them to maximize the quality and duration of their lives and their families, changing the way in which the world conceives genetics.
Veritas was the first company to offer whole genome sequencing and interpretation to consumers and their physicians and leads the field of genetics, expanding the limits of science and technology and reducing the cost of the genome.
Veritas was founded in 2014 by leaders in genomics at the Harvard Medical School and operates worldwide from its offices in the United States, Europe and China. The company has been recognized by MIT Technology Review as one of the 50 Smartest Companies in 2016 and 2017, by Fast Company as one of the most innovative healthcare companies in the world in 2018, and by CNBC as one of the Disruptor 50 companies in 2018.